Report
David Seynnaeve, PhD

Onward Medical NV - Q3 update - ARC-EX timeline reconfirmed

*This morning, ONWD provided a Q3 operational and financial update, most notably reconfirming 1/ the ARC-EX commercial timeline – launch foreseen in H2 2024 and 2/ the cash runway until 2024 end. The company indicated that they will look for ways to strengthen their cash position in the months to come.*Also, ONWD slightly revised the Empower-BP study launch timing (H2 vs. mid-2024 before) and UP-Lift trial data release (2024 vs. 2023).*We stick to our Buy rating and will come back shortly with an updated TP following the previously announced delayed commercial timeline for ARC-EX and USD 30k price guidance for
Underlying
ONWARD MEDICAL NV

Provider
Degroof Petercam
Degroof Petercam

​We are an investment house with Belgian roots founded on more than 150 years of trust.

As a private company owned by long-term committed shareholders, we are independent. Naturally and structurally. Our experts have the knowledge to think and act without bias, and to make decisions that benefit our clients. Today and tomorrow.

Analysts
David Seynnaeve, PhD

Other Reports on these Companies
Other Reports from Degroof Petercam

ResearchPool Subscriptions

Get the most out of your insights

Get in touch